Corporate Venture Capital – An Alternative Route To Finance? (September 2009)

Choosing The UK For Translational Medicine (June 2009)

Has The Downturn Changed Dealmaking? (June 2009)

What You Should Know About REACH (Life Science Leader, May 2009)

The Rising Problem of Parallel Trade (March 2009)

Start-Up: Windhover's Review of Emerging Medical Ventures:

Mesynthes Ltd (October 2009)

Silicos NV (October 2009)

Molteni Therapeutics SRL (September 2009)

Savara Inc (July 2009)

Immune Targeting Systems Ltd (June 2009)

Marinomed Biotechnologie GMBH (June 2009)

PCI Biotech Holding (April 2009)

Med Discovery (March 2009)

Itero Biopharmaceuticals (February 2009)

Dimerix Bioscience (February 2009)

Spinifex Pharmaceuticals (January 2009)

SmartCells (December 2008)

KM Medical (November 2008)

MedGenesis Therapeutix (July 2008)

ProtAb (June 2008)

Pronostics (June 2008)

InterMed Discovery (April 2008)

Activaero (March 2008)

Lytix Biopharma (February 2008)

Cizzle Biotechnology (January 2008)

ActoGeniX (December 2007)

Anaptys Biosciences (November 2007)

ProtAffin Biotechnologie (October 2007)

GlycoVaxyn (September 2007)

New Zealand Biotech: a review (July 2007)

CoDa Therapeutics (July 2007)

ProActa (July 2007)

Protemix (July 2007)

Vaxon Biotech (June 2007)

ImVisioN (June 2007)

Opsona Therapeutics (May 2007)

PharmaKodex (April 2007)

Syntaxin (March 2007)

Enigma Diagnostics (February 2007)

Plethora (January 2007)

Syntopix (November 2007)

Scrip Drug & Market Development:

Company spotlight: Cizzle Biotechnology (Scrip Drug & Market Development, July 2008)

CRfocus:

Reputation of the pharmaceutical industry: The role of communications & People in Research (CRfocus, July 2008)

A pocket guide to clinical research in India (CRfocus, July 2008)

A day in the life of a sample (CRfocus, July 2008)

Is tuberculosis under control? (CRfocus, July 2008)

Nature Biotechnology supplements:

Special report: Scandinavian biotech (Nature Biotechnology supplement, June 2008)

Biopharma Dealmakers October 2009

BioPharma Dealmakers May 2009

Scrip supplement:

Why work in UK biopharma? (Scrip supplement, June 2008)

Pesticide & Toxic Chemical News:

Environmental group raises concerns over EPA's triclosan risk assessment (Pesticide and Toxic Chemical News, May 2008)

TJOLS:

A Fledgling Drug-making Process (TJOLS, November 2007)

Pharmalicensing:

Endo Pharmaceuticals/Vernalis' frovatriptan: The partnership of 2004 (2005)

India: The emerging R&D collaborative opportunity (2005)

Foamix: Taking the skincare market by storm (2005)

Amarin Corporation: Focusing on CNS (2005)

Adjuvantix: enabling a new generation of vaccines (2004)

NameDesigner: focusing on the brand (2004)

Glucomed: Focus on quality (2004)

UCL Biomedica (2004)

Cetek: Leads from nature (2004)

Patents, IP strategy and the development of pharmaceuticals (2004)

PRO-MED: Smart drug delivery (2004)

TransDermal Technologies (2004)

ESBATech: Therapeutic antibody fragments for local applications (2004)

Alliance Pharmaceuticals: The little 'big pharma' (2003)

Chemical Diversity Labs: Diversity through collaboration through collaboration (2003)

Nektar: Delivering on its promise (2003)

Amarin Corporation: More than drug delivery (2003)

Amersham Health: predicting and diagnosing disease2003)

Early Stage and Discovery Deals: Strategy, Structure and Payment Terms (link to buy report)